Brief: Marker Therapeutics Reports Q3 2022 Operating And Financial Results
10/11/2022 21:52
Nov 10 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS REPORTS Q3 2022 OPERATING AND
FINANCIAL
RESULTS
* MARKER THERAPEUTICS INC - AT SEPTEMBER 30, 2022, MARKER
HAD CASH
AND CASH EQUIVALENTS OF $18.1 MILLION
* MARKER THERAPEUTICS INC- QTRLY NET LOSS PER SHARE, BASIC
AND
DILUTED $0.08
Source text for Eikon: ID:nGNX9d2LlS
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79